Colorectal peritoneal metastases (CPM) are associated with abbreviated survival and significantly impaired quality of life. In patients with CPM, radical multimodality treatment consisting of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated oncological superiority over systemic chemotherapy alone. In highly selected patients undergoing CRS + HIPEC, overall survival of over 60% has been reported in some series. These are patients in whom the disease burden is limited and where the diagnosis is made at an early stage in the disease course. Early diagnosis and a deeper understanding of the biological mechanisms that regulate CPM are critical to refining patient selection for radical treatment, personalising therapeutic approaches, enhancing prognostication, and ultimately improving long-term survivorship. In the present study, we outline three broad themes which represent critical future research targets in CPM: (1) enhanced radiological strategies for early detection and staging; (2) identification and validation of translational biomarkers for diagnostic, prognostic, and therapeutic deployment; and (3) development of optimized approaches for surgical cytoreduction as well as more precise strategies for intraperitoneal drug selection and delivery. Herein, we provide a contemporary narrative review of the state of the art in these three areas. A systematic review in accordance with PRISMA guidelines was undertaken on all English language studies published between 2007 and 2017. In vitro and animal model studies were deemed eligible for inclusion in the sections pertaining to biomarkers and therapeutic optimisation, as these areas of research currently remain in the early stages of development. Acquired data were then divided into hierarchical thematic categories (imaging modalities, translational biomarkers (diagnostic/prognostic/therapeutic), and delivery techniques) and subcategories. An interactive sunburst figure is provided for intuitive interrogation of the CPM research landscape.
Introduction
Colorectal peritoneal metastases (CPM) are identified in 5-10% of patients undergoing colorectal cancer resection, and metachronous CPM occur in an estimated 20-50% of patients during follow-up [1] [2] [3] . Peritoneal dissemination is associated with abbreviated survival and significantly impaired quality of life. Survival for patients with CPM ranges from 5 months in untreated cases to an estimated 12-18 months with modern systemic chemotherapy (including biologicals) [1] [2] [3] [4] [5] [6] . Several recent studies have shown substantially shorter survival with CPM as compared with nonperitoneal colorectal metastases [7] ; this is likely owing to biological and histological differences as well as the relative chemoimpenetrability of the peritoneal cavity compared with visceral metastatic sites [7] . The diagnosis of CPM is often made at an advanced stage due to the lack of specific symptoms of peritoneal involvement and the low sensitivity of current imaging techniques. In select cases, the diagnosis of CPM is established at an earlier stage where multimodality treatment in the form of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered. The combination of CRS and HIPEC was popularized by Sugarbaker et al. in the early 1990s [8] , and the oncological superiority of this approach over systemic chemotherapy in isolation has been confirmed by several recent phase II and III clinical trials [9] .
Data synthesized from multicentre analyses report median overall survival rates of up to 63% in highly selected patients undergoing CRS and HIPEC [5, [10] [11] [12] [13] . Concurrently, the reported 1-year mortality rate and recurrence rate after CRS and HIPEC are estimated to be 13% and 35%, respectively [14] . Several points of discussion emerge from these data; firstly, increased survival is possible in a select group of patients with CPM, and so more accurate modalities are needed with which to identify these patients early on in the disease course; secondly, up to one third of patients offered CRS and HIPEC relapse within 12 months, and therefore, more robust methods for identifying these patients prior to radical treatment should be developed-either with a view to avoiding radical surgery altogether or developing novel ways of modifying the risk of relapse/enhancing the therapeutic response. Beyond these aspects, further improvements in survival for patients with CPM will require a deeper understanding of the molecular processes that drive peritoneal spread and those that dictate peritoneal chemosensitivity. In addition, the techniques of CRS and HIPEC, including approaches to drug selection and drug delivery, have undergone only superficial modification since the original description proposed by Sugarbaker. Extrapolating further from these points, three definable areas emerge as critical future research targets in CPM: (1) enhanced strategies for early detection; (2) identification and validation of translational biomarkers for diagnostic, prognostic, and therapeutic utility in CPM; and (3) development of optimized approaches for surgical treatment as well as more precise strategies for intraperitoneal drug selection and delivery. In the present article, we provide a contemporary narrative review of the state of the art in these three areas. The following medical subject heading (MeSH) terms and keywords were used: "colorectal," "peritoneal," "metastases," "cytoreductive surgery," "HIPEC," and "intra-peritoneal chemotherapy." The "related articles" function was used to broaden the search, and all abstracts, studies, and citations retrieved were scanned for subject relevance. The latest date of this search was November 2017. All potentially relevant publications were retrieved in full text and formally evaluated for study inclusion. Reference lists of all relevant publications were hand-searched for additional studies missed by the search strategy, and this method of cross-referencing was continued until no further relevant publications were identified.
Study Inclusion Criteria and Data Extraction.
Study methodology was carried out in accordance with the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) recommendations for improving the standard of systematic reviews [15] . Studies that met the following predefined criteria were included in the review process: Language: only English language publications were included. Patient population: studies had to report outcome data specifically on the use/investigation of one or more of the following: (i) radiological/imaging approaches for diagnosis and staging of CPM; (ii) novel techniques for treatment of CPM including pharmacological and/or surgical approaches-novelty here was defined as any therapeutic approach described and evaluated beyond conventional CRS + HIPEC (defined as complete macroscopic resection of parietal and visceral peritoneal carcinomatosis combined with hyperthermic intraperitoneal chemotherapy); and (iii) biomarkers for CPM diagnosis, prognosis, and therapy. Studies reporting on in vitro or animal model data were considered eligible for inclusion for sections pertaining to novel technical approaches, translational biomarkers, and therapeutic optimisation. For imaging studies, included studies had to provide data on modality-specific sensitivity, specificity, or other metric representative of accuracy of the radiological technique employed. In the event that studies were found to provide data deemed admissible across more than one of these domains (e.g., a study providing data on outcomes for a radiological technique as well as data on therapeutic approach and/or biomarkers), then this data would be included separately under the relevant subheadings in the review process and results. Studies reporting data for CPM as well as peritoneal metastases of other origin(s) were excluded unless specific outcome data pertaining to CPM was disclosed by the authors. Type of intraperitoneal chemotherapy: studies reporting on all established and experimental methods of intraperitoneal chemotherapy were included. Previous treatment: studies reporting on previously treated patients with CPM were included. Where multiple studies describing the same patient population were identified, the most recent publication was used unless additional information was imparted by earlier work. In cases of doubt, authors were contacted for further information to ensure accuracy or for additional data. Figure 1 depicts the screening process for selection of potentially relevant studies. Two reviewers (SK and DX) independently extracted the following data from all eligible studies according to a predetermined protocol: first author, year of publication, study location, study type, study time frame, population characteristics, number of subjects, and biomarker investigated (where applicable); radiological/-nonradiological technique for detection/surveillance (where applicable); intraperitoneal chemotherapy administration technique used (where applicable); and key findings.
Data Analysis and Data
Representation. Data acquired via the outlined search strategy was divided into hierarchical thematic categories (imaging modalities, translational biomarkers (diagnostic/prognostic/therapeutic), and delivery techniques) and subcategories. To create a visually intuitive figure for assessment of the CPM research landscape, the number of publications within a given hierarchical category and subcategories has been displayed in the form of a sunburst visualization figure (Figure 2 ). In this plot, the "upper-level" broad hierarchical categories (imaging/biomarkers/delivery techniques) are represented by the inner figure arches that subsequently divide into more specific subcategories. The circumference of each arch indicates the proportion of publications belonging to a given category/subcategory relative to the rest of the publications in the same hierarchical level. The resulting plot was generated using the D3 JavaScript library.
Results

Imaging
3.1.1. Radiological Diagnosis and Staging of CPM. Predefined search criteria identified 19 studies evaluating different radiological modalities for detection and staging of CPM (Table 1 ) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Six studies assessed the utility of computed tomography (CT) imaging in this context [19, 23, [31] [32] [33] [34] with reported sensitivity and specificity ranging from 11-96% and 49-100%, respectively. The considerable variability in sensitivity with CT has been ascribed to between-study heterogeneity in terms of anatomical site of lesion(s) detected and lesion size [19, 22, 31, 32] . Studies where per-region analysis was performed indicate that areas where CT achieves highest sensitivity are the epigastrium (67-98%) [19, 32] , the left upper quadrant (40-86%) [19, 32] , and the pelvis (60-73%) [19, 32] . In contrast, regions where CT Full-text articles excluded (n = 80):
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Figure 1: Modified preferred reporting items for systematic reviews and meta-analysis flow diagram outlining study selection strategy.
achieves the lowest sensitivity for lesion detection on CT were found to be the small bowel (8-71%) [19, 23, 32] and adjacent to the ligament of Treitz (20%) [23] . Subanalysis based on lesion size demonstrates a positive correlation between sensitivity of CT for lesion detection and lesion size, with sensitivity ranging from 11 to 70% for lesions under 0.5 cm in size, compared with 90-94% for lesions greater than 3 cm [19, 23, 31] . All three studies [19, 23, 31] used a similar oral and intravenous contrast protocol; however, differences in CT slice thickness, lesion size cut-off values, and lesion site(s) are likely to be responsible for the wide range in sensitivity (11-70% in the case of lesions under 0.5 cm).
In terms of estimation of CPM burden, Koh et al. found that the CT-defined peritoneal carcinomatosis index (CT-PCI) significantly underestimated the disease extent compared to surgical PCI (S-PCI; p < 0 001) [19] . However, correlation analysis carried out in two other studies showed a favourable correlation between CT-PCI and S-PCI scores [31, 33] . A recent meta-analysis by Laghi et al. also reported a good correlation between CT-PCI and S-PCI, though the authors did note the potential for CT to underestimate PCI by 12-33% [25] . Several authors have shown that underestimation of PCI with CT is diminished somewhat when a PCI cut-off of 20 is employed [32, 33] .
Four [16] [17] [18] 22] studies provided data on PET/CT for assessment of CPM. Liberale et al. [22] reported sensitivity and specificity of 85% and 88%, respectively, for detection of CPM using PET/CT. Four studies compared PET/CT to CT [20, 24, 28, 30] with two reporting significantly lower sensitivity with PET/CT compared to CT (82% vs. 91% [24] ; 57% vs. 82% [30] ). Conversely, a retrospective evaluation of 23 patients with CPM by Bamba et al. [20] demonstrated markedly improved detection accuracy with PET/CT compared to conventional CT (82.6 vs. 30% [20] ). In terms of postsurgical surveillance of CPM, Choi et al. showed that PET/CT had higher sensitivity for detecting peritoneal recurrence compared to CT, both compared to histopathological confirmation (100% vs. 85.1%) [28] . In all of these studies, gold standards for confirming diagnosis of CPM and assessing PCI were defined as histological confirmation and surgical PCI estimation, respectively [16-18, 20, 22, 24, 28, 30] . The wide variation in reported sensitivity and moreover the opposing findings reported by some authors regarding the role of PET is difficult to robustly account for. However, at least in part it is likely related to the fundamental fact that PET relies on changes in glucose metabolism, which can vary widely between tumours in a given study cohort; for example, mucinous and signet ring cell carcinomas will tend to exhibit relatively little 18 F-FDG uptake compared to other histological subtypes.
No studies were identified reporting exclusively on MRI in CPM detection, though four [25] [26] [27] 29] were found that compared or combined MRI with alternative diagnostic imaging modalities. Brendle et al. [27] compared the diagnostic accuracy of PET/CT, PET/MRI, and diffusionweighted MRI (MRI-DWI) and found that conventional MRI alone had inferior diagnostic accuracy compared to when combined with DWI or PET or when compared with CT (diagnostic accuracy of 46%, 47%, 57%, and 66%, respectively). It is interesting to note the very modest increment in diagnostic accuracy with MRI-DWI observed in this study, as there is growing interest in the role of this approach in peritoneal malignancy, which seems difficult to justify based on these findings. Two further studies compared the accuracy of MRI with PET/CT and conventional CT/multidetector CT (MDCT) [25, 26] . Satoh et al. [26] retrospectively evaluated imaging accuracy in patients with peritoneal metastases, of varying primary origins, including colorectal. The authors found that the sensitivity, specificity, and positive predictive values of PET/CT was significantly better than those of MRI or MDCT. However, the meta-analysis performed by Laghi et al. [25] , which represents the only pooled analysis of data, failed to show a significant overall difference between CT, MRI, and PET/CT. Nonetheless, the authors did note that when evaluating studies directly comparing CT to PET/CT, sensitivity and specificity for PET/CT were higher than those of CT for detecting peritoneal metastasis (82% vs. 66% and 93% vs. 77%, respectively) [25] . It is likely that a combination of imaging approaches may offer the greatest diagnostic accuracy, and this was recently pointed out by Dohan et al. who found that the addition of MRI to CT for preoperative imaging led to a significant increase in diagnostic sensitivity (CT 54%, CT+MRI 81%; p = 0 01) [29] .
Intraoperative Imaging and Enhanced Laparoscopy.
Staging laparoscopy plays an important role in CPM assessment as it allows direct visualization of the peritoneal surface, tissue biopsy, and PCI estimation. However, Thomassen et al., and a number of other authors, have suggested that open surgery yields significantly higher diagnostic accuracy compared to laparoscopy for CPM [35] . In the present review, we identified 4 studies [22, [36] [37] [38] evaluating different techniques with which to enhance minimally invasive peritoneal lesion detection ( Table 2 ). One study reported on the application of virtual chromoendoscopy using the Fuji Flexible spectral Imaging Color Enhancement (FICE) endoscopy system [38] , and three studies described the use of fluorescence imaging approaches [36, 37, 39] . The FICE endoscopy system has ten different light wavelength patterns, or channels, which can be customised/reconfigured according to the intended application. In the study by Najah and colleagues [38] , the use of the "Channel 2" FICE wavelength showed considerable superiority over standard laparoscopic visualization for detection of peritoneal nodules.
Fluorescence imaging using indocyanine green pigment and intraoperative infrared imaging (ICG-FI and NRIF) was described in 4 studies (Table 2) [36, 37, 39, 40] . Sensitivity for peritoneal lesion detection ranged from 72.4% to 96.9%, with reported specificity ranging from 60 to 100%. When compared with conventional visual inspection of the peritoneal surface, ICG-FI displayed superior diagnostic performance (p = 0 027) and resulted in a higher median detected PCI score (10 vs. 7; p < 0 001) [37] . However, Liberale et al. [39] importantly noted that this modality was ineffective for detecting mucinous lesions. One small study including 7 human participants [40] trialled a molecular fluorescent agent linked to a tumour target (bevacizumab conjugated to the near-infrared fluorescent dye IRDye 800CW that targets tumour VEGF-A) with reported sensitivity and specificity of 100% and 54%, respectively. [46, 52, 59] , and 1 reported on outcomes of the closed technique in combination with early postoperative intraperitoneal chemotherapy (EPIC) [51] . Finally, 1 paper described a safe, low-cost delivery method using cardiac bypass pumps as an alternative to the conventional HIPEC instillation circuit [67] .
Morbidity and mortality for the open technique ranged from 43.5 to 55% and from 0 to 5.1%, respectively [52, 59, 62] . Spiliotis et al. demonstrated that a positive correlation between mortality and high PCI index, duration of surgery and blood loss, and morbidity was mainly due to pulmonary complications [62] . A number of studies have reported differences in morbidity and mortality with open versus closed delivery approaches [51, 52, 59] n: number of participants; LRM: literature review and meta-analysis; PCS: prospective cohort study; RCS: retrospective cohort study; ROS retrospective observational study; i.p.: intraperitoneal; PM: peritoneal metastasis; IHC: immunohistochemical.
Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)
. PIPAC is performed using high CO 2 pressures (12 mmHg at 37 o ) converting the intended drug, most commonly oxaliplatin, into an aerosol which is sprayed into the peritoneal cavity. Five studies reported data on PIPAC for CPM [41, 44, 49, 54, 58] . These studies present PIPAC results in the palliative setting, in patients with irresectable disease, extensive CPM, and/or those having previously undergone CRS and/or systemic chemotherapy, who were left with residual disease or developed disease recurrence at followup [41, 44, 49, 54, 58] . Treatment-associated morbidity ranged from 9.5% to 23%, the mortality from 0% to 6.8% [41, 44, 58] . Median survival post-PIPAC was 15.7 months [44] . PIPAC drug penetration and distribution was found to be 300 μm, mostly concentrated around the micropump, with low penetration in distant areas such as the stomach and subphrenic areas in a swine model [54] . Tumour response to PIPAC was insufficient when used without any additional chemotherapy regimes [58] but ranged from a PCI improvement of 50% to 88% when PIPAC was combined with systemic treatment [41, 44, 49, 58] . The toxicity of PIPAC was assessed by 2 papers and ranged from no renal or hepatic toxicity [58] to low toxicity in 42% of cases with good tumour response [44] . One study assessed the role of PIPAC in CPM for symptom management [41] where symptoms of pain, ascites, and bowel transit disorders resolved following three cycles of PIPAC in 63.3%, 60%, and 45.5%, respectively, with a 3-day median hospital stay.
Early Postoperative Intraperitoneal Chemotherapy (EPIC)
. EPIC is administered post-CRS with 5 days of intraperitoneal drug infusion, commonly using mitomycin C and 5-FU. Two studies compared EPIC with HIPEC for CPM [42, 45] . In these studies, EPIC alone was not found to be superior to HIPEC with respect to mortality, morbidity, or cancer recurrence [45] . However, the HIPEC and EPIC combination was shown to achieve greater recurrence-free survival compared with HIPEC alone [42] . The results of the ongoing ICARUS multicentre study comparing outcomes with EPIC and HIPEC in terms of effectiveness and toxicity are eagerly awaited, and this represents the first RCT of its kind in this setting.
3.3. Novel Pharmacological Delivery Methods. Our literature review identified 16 studies describing novel pharmacological drug delivery techniques for intraperitoneal chemotherapy (Table 4) . These studies can be divided into 3 subcategories: (i) linking drugs to hyaluronic acid (HA) bioconjugates [56, 61] , (ii) drug delivery vessels [43, 47, 53, 57, 63] , and (iii) hydrogels [48, 50, [64] [65] [66] 69] . No comparative study between delivery methods was identified in our literature search.
3.3.1. Linking Drugs to HA Bioconjugates. Two studies were identified describing the use of HA bioconjugates for enhanced IPEC delivery [56, 61] . Hyaluronic acid derivatives were used to increase tumour cell uptake of cytotoxic medication, shown to occur via CD44 receptor binding leading to endocytosis of the drug [56] . Linking the drug to HA led to greater tolerability and lower bone marrow toxicity compared to cytotoxic drug delivery in the free form [56, 61] . Furthermore, an HA-SN38 conjugate drug was shown to be more effective than the free drug by increasing tumour cell drug uptake and having 16 times greater antiproliferative activity in vitro and significantly smaller tumour burden and malignant ascites in vivo [61] . The authors suggest that the lower systemic toxicity of such formulations will allow their use in vulnerable patients and UGTA1 phenotype patients who are at high risk of bone marrow toxicity.
3.3.2. Drug Loading Vessels. Eight papers were identified exploring the use of drug-eluting beads (drug loading vessels that can prolong drug release) [53] and nanoparticles, nanoliposomes, microspheres, or micelles (which increase drug specificity by being internalized by tumour cells) [43, 47, 57, 63, [70] [71] [72] . Intraperitoneally placed doxorubicin and mitoxenone drug-eluting beads were shown to continuously release the drug in lower concentrations decreasing side effects and mortality [53] with a similar decline in tumour load compared to free drug. Similarly, drug-loaded microspheres were also shown to decrease tumour volume [47, 57] ; doxorubicin microspheres (50-100 μm) were shown to significantly decrease tumour volume compared to blank microspheres and induce coagulative necrosis [57] . Docetaxel microspheres (45 μm) were also shown to significantly decrease CPM tissue Ki-67 markers and significantly increase median survival in animal models [47] .
Nanoliposomes are self-assembling particles made of a lipid bilayer that encloses soluble drugs. Due to enhanced permeability and retention in tumour cells, nanoliposomes can achieve selective uptake by tumour cells, increasing antitumour efficacy whilst minimising collateral side effects [73] . In one study, it was found that drug delivery using IV 188Re-liposomes increased survival by 34% (p < 0 05) and decreased tumour volume and ascites by 63.4% and 83.3%, respectively, at 7 days after treatment in mice (p < 0 05) [70] . In 2007, a phase I study using PLC (doxorubicin encapsulated in liposomes) as part of the HIPEC regime in 29 patients found nanoliposomes to be well tolerated, resulting in a more favourable side effect profile and overall survival of 30.6 months [72] .
Expansile nanoparticles (100 nm diameter) were also shown to significantly decrease tumour mass and disease severity score (DSS) compared to free drug and control, with no major systemic toxicities in a CPM mouse model [43] . Biodegradable micelles (25 nm diameter) were also identified as vessels for novel chemotherapeutic agents such as the antibacterial chetomin. Even when using this novel agent, drug micelle delivery significantly decreased tumour volume, tumour vessel length, and branching compared to the free drug in CPM [63] . The chetomin micelles were further used to create a hydrogel that significantly decreased tumour weight compared to micelles and free drug (p < 0 01) in a CPM mouse model [63] .
3.3.3. Linking Drug to Hydrogels. The potential of cytotoxic drugs imbedded in hydrogels was evaluated in six studies [48, 50, [64] [65] [66] 69] . All hydrogels used were mildly cytotoxic at very high concentrations but well tolerated otherwise in animal models. The hydrogels are combined with drug vessels making composite drug delivery systems. Two of the six studies used nanoparticles in hydrogel [48, 64] , three used micelles in hydrogel [50, 65, 66] , and one used biodegradable microspheres in hydrogel [69] . All hydrogel composites used were thermosensitive, enabling them to remain solid intraperitoneally and offer a slower release drug formulation [66] . They were found to significantly suppress cell growth in vitro [48, 64] , increase tumour cell apoptosis [66] , and decrease microvessel formation [66] . Four studies also showed that vessel and hydrogel composites significantly decreased tumour nodule weight and number [50, 65, 66, 69] compared with free drug delivery. In animal models, cancer-specific survival was shown to be significantly enhanced in the hydrogel group compared to the free intraperitoneal drug delivery [48, 50, 65, 66] . Furthermore, the combination of microspheres or micelles with a hydrogel was shown to be significantly superior in decreasing tumour weight and number compared to free drug and to the drug in the vessel [66, 69] .
3.4. Biomarkers. Predefined search criteria identified 24 studies evaluating the role of biomarkers in the diagnosis, prognosis, and treatment of CPM (Table 5) .
3.4.1. Diagnostic Biomarkers. Five studies [76, 83, 84, 89, 97] were identified assessing the value of CEA, CA125, and Ca19-9 as diagnostic biomarkers in CPM; evaluating their sensitivity and specificity for CPM diagnosis; and comparing them to conventional imaging.
Significantly higher levels of CA125 were detected in patients with CPM, with CA125 concentration positively correlating with CPM tumour volume [89] . Subanalysis based on primary lesion site showed that CA125 concentration differed amongst patients with CPM originating from left-versus right-sided colon primaries (p < 0 001). Interestingly, this study reported a similar trend for CEA, but only in female patients. In male patients, CEA levels increased with increasing stage of CRC according to UICC classification, but were not consistently raised in patients with isolated CPM. Huang et al. [89] found CA125 to have higher sensitivity in diagnosing CPM compared with CT imaging. This study again reported inferior diagnostic accuracy and sensitivity with CEA compared to CA125 [89] . However, these findings should be interpreted with caution, as the study by Huang and colleagues is subject to several limitations. Firstly, they employed a CPM staging tool that is not widely used (PD score), and so the generalisability of the results is unclear. Secondly, the study lacks a gold standard on which to base diagnostic accuracy. They have compared CT with tumour marker profiling, and in the case of CPM, neither represent a valid benchmark.
Two studies [83, 97] were identified that evaluated the predictive value of CEA and Ca 19-9 (cut-off used 37.0 U/ml) in diagnosing synchronous peritoneal metastases in patients with CRC. Both demonstrated that elevated levels of Ca19-9 were significantly associated with the presence of CPM, whereas CEA did not retain its significant value in multivariate analysis. Lee et al. also found that intraperitoneal CEA levels were significantly correlated with recurrence and peritoneal metastasis, in patients with negative peritoneal cytology, allowing for a measurement of a marker that could aid in developing stratified follow-up regimens for early detection of CPM in high-risk patients [76] .
3.4.2. Prognostic Biomarkers. Seven studies found CEA to be a prognostic marker of overall survival [76, 80, 81, 83, 87, 91, 92] . Cut-off thresholds for CEA showed marked variability between the different studies and ranged from CEA > 5 ng/ml to CEA > 70 mg/l. Irrespective of these differences, all authors found that pre-op CEA levels greater than the assigned cut-off value were associated with poor prognosis, reduced overall survival (OS), and impaired disease-free survival.
Interestingly, Ozawa and colleagues [81] failed to demonstrate the prognostic value of CEA in multivariate analysis but found that preoperative CEA correlates with likelihood of complete cytoreduction (CR0).
The BRAF phenotype in association with CPM was evaluated by 3 studies [88, 90, 96] . Tumours with the BRAF mutation were more likely to present with peritoneal metastases and aggressive biology [98] . Sasaki et al. observed that BRAF V600E mutation was more prevalent in patients with CPM as compared to those without [90] .
Bong et al. [91] and Ihemelandu et al. [95] evaluated the platelet-to-lymphocyte ratio (PLR), and this marker was shown to be an independent prognostic factor of poor OS, in levels exceeding 200 and 300, respectively. Patients with a PLR of 150-300 had a median OS of 36 months, and those with a PLR < 150 had an OS of 47 months. PLR was established to be a significant prognostic factor in predicting 5-year OS [72] .
Vascular endothelial growth factor (VEGF) was found to be evaluated as a prognostic factor in 3 studies [87, 93, 94] . Chia et al. [87] showed that lower levels of intraperitoneal VEGF at the time of abdominal cavity exploration were associated with improved overall survival in patients with CPM. A similar finding was reported by de Cuba et al. [93] and Sluiter et al. [94] with both studies demonstrating a significant association between high tissue VEGF expression and reduced overall survival in CPM. Sluiter et al. [94] also identified epithelial and stromal VCAN expression as a potential marker of improved overall survival.
The latest study by Ubink et al. [99] showed the relationship between consensus molecular subtype (CMS) and occurrence of CPM. CMS4-positive tumours are more likely to present with peritoneal metastases. Furthermore, those cancers have been associated with a poorer response to anticancer drugs, such as oxaliplatin. However, to confirm its suspected resistance to oxaliplatin, further prospective studies should be conducted.
3.4.3. Therapeutic Biomarkers. Eight studies [74, 75, 78, 79, [86] [87] [88] 93] were identified evaluating biomarkers for therapeutic monitoring in CPM. Biomarkers evaluated were ERCC1, TS, VEGF, CTGF, and CRC gene expression.
ERCC1 and TS expression levels have shown some predictive relevance but no clear relationship with regards to response and resistance to 5FU and oxaliplatin containing therapeutic regimens [79] . One study showed in vitro chemosensitivity testing to be more effective in predicting clinical response to treatment than the aforementioned biomarkers [79] ; however, the expression of these markers demonstrated a direct relationship with clinical response to 5FU and/or oxaliplatin-containing combinations.
Another study [86] demonstrated a significant correlation between high BRCA2 gene expression and BLM gene and protein expression with resistance to mitomycin C (MMC) therapy in peritoneal carcinomatosis.
Five studies [75, 78, 87, 88, 93] have proposed further research into targeted treatments that amplify or reduce biomarker expression or that intervene in pathways which have shown significant association with survival and response to treatment in peritoneal carcinomatosis. Varghese et al. [74] demonstrated distinct gene upregulation of IGF1, HIF1, TIMP2, mTOH, COH17, and MSLN in peritoneal metastasis compared to other metastatic sites, suggesting a role for these molecular targets in peritoneal dissemination of colorectal cancer and furthermore indicating a possible role for these targets in the development of peritoneal surface specific anticancer treatments.
Logan-Collins [75] et al. and de Cuba et al. [93] evaluated VEGF expression levels in patients undergoing CRS and HIPEC and found that high VEGF expression was associated with poor overall survival following treatment, identifying VEGF as a promising treatment target and also a useful marker that could identify patients at risk of early treatment failure. Chia et al. [87] demonstrated that low preoperative intraperitoneal (IP) VEGF levels were associated with improved survival and suggest that bevacizumab, which selectively targets the VEGF receptor, could be selectively used in these patients to improve disease control.
Data in a study by Lin and colleagues [78] demonstrated that CTGF has a role in inhibiting colorectal cancer cell adhesion (a crucial step in peritoneal seeding), highlighting the potential to use CTGF for the development of targeted therapies that dampen cell adhesion and mitigate peritoneal seeding.
Discussion
Improving survival for patients with colorectal peritoneal metastases (CPM) will require advances in radiological assessment, identification and validation of translational biomarkers, and enhancements to surgical cytoreduction and intraperitoneal drug delivery. The aim of the present study was to provide a systematic overview of recent developments across these three broad research domains; acquired data have been integrated into a sunburst figure, offering a means of interactively evaluating the CPM research landscape. The data provided herein represent a streamlined overview of the available literature on CPM, and this is primarily due to strict methodological adherence to predefined criteria for study inclusion. Studies were only included if they provided quantitative data on performance of radiological techniques, outcome data on novel delivery/treatment methods, or where they investigated disease biomarkers. In addition, studies were only included where data on CPM were specifically provided.
In terms of radiological diagnosis and staging, there remains ongoing uncertainty regarding the optimal imaging modality/combination of modalities and the available literature is highly heterogeneous. Computed tomography is currently the most widely used approach due to its versatility and availability. However, as the studies presented in this review demonstrate, CT appears to consistently underestimate PCI compared with surgical findings and has poor sensitivity for plaque-like nodules and those measuring <0.5 cm [19] . Although MRI, and in particular diffusion-weighted MRI, has gained increasing attention in recent years, there remain practical limitations with this approach due to extended scan duration, patient-related contraindications, and limited capacity of MRI scanning facilities compared with CT. Therefore, at the present time, and despite the aforementioned limitations, CT is generally considered to represent the initial imaging technique of choice for evaluating patients with CPM. One way to offset some of the disadvantages of CT is to introduce formal standardisation of image reporting for peritoneal disease. The introduction of proforma-based reporting has had a significantly positive impact on decision-making in regards to multimodality therapy and operative planning in rectal cancer [104] . Evaluation of CPM extent and distribution would benefit from similar standardisation though this has yet to see widespread implementation. The PAUSE algorithm proposed by Chandramohan and colleagues offers an elegant solution designed to provide a common language for communicating imaging findings in CPM [105] . Briefly, the acronym incorporates: P (primary tumour and peritoneal carcinomatosis index), A (ascites and abdominal wall involvement), U (unfavourable sites of involvement), S (small bowel and mesenteric disease), and E (extraperitoneal metastases). Employing this approach should improve the accuracy of CT reporting in CPM, and widespread implementation will help to improve the consistency of data being accumulated in multinational CPM registries. Besides standardisation of reporting strategy, it is also important to try and firmly establish an optimal protocol for CT imaging of peritoneal disease, and there remains considerable variation in practice across institutions. It is, however, generally accepted that the use of positive or neutral oral contrast medium to opacify the small bowel is useful in evaluating involvement of small bowel and its associated mesentery. Our practice involves multidetector CT image acquisition at section thickness of 3 mm. Patients are given 750-1000 ml of water orally 15 minutes prior to the study, together with intravenous contrast administration. Arterial and venous phase image acquisition is then performed 30 and 60 seconds following contrast injection, respectively. Derived scans are evaluated in protocol-driven fashion in a dedicated complex colorectal cancer multidisciplinary meeting, using axial as well as multiplanar reconstructed images.
Adjunct techniques such as portal venous embolization and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) have revolutionised treatment options in colorectal cancer liver metastases and similar innovative approaches need to be developed for CPM in the future. With regards to technical advancements, PIPAC represents the most radical proposed departure from standard approaches to intraperitoneal chemotherapy. It is designed to generate an artificial pressure gradient enhancing tissue uptake and permitting homogeneous drug distribution within a closed and expanded abdominal cavity. Early experimental work has demonstrated favourable effects of delivering therapy under pressure of pneumoperitoneum, as this appears to counteract elevated intratumoural interstitial fluid pressures and thus enhances drug uptake. Though PIPAC has until now primarily been reserved for symptom control in the palliative setting, there is some emerging evidence to suggest that it can be utilized in the neoadjuvant setting, with the aim of downstaging disease and facilitating subsequent attempts at radical cytoreduction and HIPEC [49] .
The data acquired from this review indicate that strategies for enhancing intraperitoneal cytotoxic effectiveness, via bioconjugation or other approach, remain primarily in the experimental phase of development. Most studies have used in vitro models or in vivo animal models. This branch of research in peritoneal malignancy needs urgently to make the transition into carefully designed prospective, ideally randomized, human studies.
In terms of biomarkers, although a growing number of studies are seeking to evaluate translational biomarkers in CPM, none beyond established tumour markers such as CEA, CA 19-9, and CA 125 have effectively made the transition to clinical use, and current evidence in the literature on the relative diagnostic and prognostic utility of these also seems somewhat contradictory. There is an urgent need to derive and validate biomarkers or biomarker panels capable of (1) defining risk of peritoneal relapse at the time of primary cancer diagnosis, (2) diagnosing disease at the early stages of peritoneal dissemination, and (3) identifying markers capable of predicting likely response to a given intraperitoneal chemotherapeutic agent. This level of translational discovery will call for allied initiatives between peritoneal malignancy institutions and biomolecular phenotyping laboratories, ideally within facilities capable of in vitro modelling as well as in vivo animal models, before initiation of human trials. Emerging disruptive technologies such as the iKnife [106] and the MasSpec Pen [107] offer the potential for real-time intraoperative phenotyping, and this perhaps holds the greatest promise in terms of realising the goal of personalised, "off-the-rack," selection of intraperitoneal chemotherapy. Simultaneously, developing a better basic understanding of what makes the peritoneum "tick" both in health and in disease should allow the development of more effective imaging biomarkers that selectively localise to the peritoneal surface and reveal disease location and volume more precisely. Moreover, a deeper understanding of the mechanisms that regulate the peritoneum should allow the development of peritoneum-specific targeted therapies that overcome the conventional limitations posed to systemic agents by the plasma-peritoneum barrier. This in turn could improve the likelihood of converting inoperable CPM cases to operable, in the same way that this has been achieved for colorectal cancer liver metastases.
Conclusion
The present study provides a contemporary "snapshot" of the CPM research landscape and summarises current and emerging trends in practice and also highlights potential areas of unmet need. The combination of more precise radiological detection, optimized therapeutics and a deeper understanding of the biological basis for CPM will lead to improvements in survivorship comparable to those seen over the past few decades in colorectal cancer liver metastases. Tertiary referral units with expertise in peritoneal surface malignancy will likely serve as hubs of translational and clinical research in the future with efforts focused on addressing specific research objectives across the three domains outlined here. Clinical and research pathways for the CPM patients should run in parallel longitudinally to generate meaningful clinical, radiological, and molecular phenotyping data at all steps through the CPM patient journey (diagnosis → staging → treatment → prognostication → surveillance).
